Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an update.
Xuanzhu Biopharmaceutical, the innovative drug arm of Sihuan Pharmaceutical, has been added to the Hang Seng Composite Index following the latest quarterly review, effective 9 March 2026. The index covers Hong Kong Main Board companies comprising the top 95% by market capitalisation, and inclusion signals stronger market recognition of Xuanzhu Biopharm’s growth prospects.
The move is expected to qualify Xuanzhu Biopharm shares for trading via the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes, broadening access to mainland investors and improving liquidity. Sihuan expects the development to expand Xuanzhu Biopharm’s investor base, enhance its valuation and reputation, and support the group’s broader strategy of strengthening its innovative pharmaceutical and medical aesthetics businesses.
Management believes the index inclusion validates the group’s innovation-driven layout and long-term drug development strategy and will positively impact both Xuanzhu Biopharm and the parent company. The group plans to continue backing Xuanzhu’s R&D and commercialisation capabilities while deepening its global footprint to deliver greater value to shareholders and partners.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is an international medical aesthetics and pharmaceutical company founded in 2001 and listed in Hong Kong since 2010. Led by innovation, it operates independent R&D platforms, a broad global product pipeline and cost-efficient manufacturing across full dosage forms, aiming to become a leading Chinese player in medical aesthetics and biopharmaceuticals.
Xuanzhu Biopharmaceutical, Sihuan’s innovative drug subsidiary, focuses on major diseases such as digestive disorders, oncology and non-alcoholic steatohepatitis. With dual R&D platforms in small molecule chemistry and large molecule biologics, it develops class 1 drugs with proprietary IP, including ADCs, targeting unmet clinical needs in China and global markets.
YTD Price Performance: 33.33%
Average Trading Volume: 28,856,532
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.3B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.